To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Uropathogen Resistance an… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Uropathogen Resistance and Antibiotic Prophylaxis: A Meta-analysis

Journal article
Authors R. E. Selekman
D. J. Shapiro
J. Boscardin
G. Williams
J. C. Craig
Per Brandström
M. Pennesi
G. Roussey-Kesler
P. Hari
H. L. Copp
Published in Pediatrics
Volume 142
Issue 1
ISSN 0031-4005
Publication year 2018
Published at Institute of Clinical Sciences, Department of Pediatrics
Language en
Keywords urinary-tract-infection, pediatric vesicoureteral reflux, controlled-trial, preventing pyelonephritis, risk-factors, renal scars, children, management, patterns, therapy, Pediatrics, rsimonian r, 1986, controlled clinical trials, v7, p177
Subject categories Pediatrics


CONTEXT: Limited data exist regarding uropathogen resistance in randomized controlled trials of urinary tract infection (UTI) prevention and antibiotic prophylaxis. OBJECTIVE: To assess the effect of prophylaxis on developing a multidrug-resistant first recurrent UTI among children with vesicoureteral reflux. DATA SOURCES: Cochrane Kidney and Transplant Specialized Register through May 25, 2017. STUDY SELECTION: Randomized controlled trials of patients 18 years of age with a history of vesicoureteral reflux being treated with continuous antibiotic prophylaxis compared with no treatment or placebo with available antibiotic sensitivity profiles. DATA EXTRACTION: Two independent observers abstracted data and assessed quality and validity per Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Adjusted meta-analyses were performed by using a mixed-effects logistic regression model. RESULTS: One thousand two hundred and ninety-nine patients contributed 224 UTIs. Patients treated with prophylaxis were more likely to have a multidrug-resistant infection (33% vs 6%, P < .001) and were more likely to receive broad-spectrum antibiotics (68% vs 49%, P = .004). Those receiving prophylaxis had 6.4 times the odds (95% confidence interval: 2.7-15.6) of developing a multidrug-resistant infection. One multidrug-resistant infection would develop for every 21 reflux patients treated with prophylaxis. LIMITATIONS: Variables that may contribute to resistance such as medication adherence and antibiotic exposure for other illnesses could not be evaluated. CONCLUSIONS: Prophylaxis increases the risk of multidrug resistance among recurrent infections. This has important implications in the risk-benefit assessment of prophylaxis as a management strategy and in the selection of empirical treatment of breakthrough infections in prophylaxis patients.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?